<DOC>
	<DOCNO>NCT01319344</DOCNO>
	<brief_summary>Patients metabolic syndrome ( MetSyn ) increase risk cardiovascular mortality morbidity.This increase cardiovascular risk attribute metabolic dysregulations like impaired glucose tolerance diabetes mellitus dyslipidemia , abdominal obesity arterial hypertension , promote oxidative stress inflammation consecutive endothelial dysfunction cause atherogenic environment . Aldosterone promote end organ damage mainly find cardiovascular system kidney . Inflammation activation different factor promotes fibroblast growth matrix production result myocardial fibrosis , vascular remodelling renal fibrosis . MetSyn aldosterone cardiovascular risk factor crucial importance note connection MetSyn aldosterone . Other cross sectional study show direct correlation aldosterone level impair glucose metabolism patient without MetSyn . Taken together , aldosterone influence essential parameter MetSyn . Coincidentally parameter MetSyn stimulus increase aldosterone synthesis , i.e . visceral adipocytes . In large scale clinical trial - RALES , EPHESUS , 4E - inhibition MR proven beneficial patient congestive heart failure post myocardial infarction result confirm diabetic patient , know increase cardiovascular risk . There limited data impact MR inhibition metabolic , endocrine , inflammatory parameter patient MetSyn , yet suffer cardiovascular event .</brief_summary>
	<brief_title>Effect Eplerenone Endothelial Function Metabolic Syndrome</brief_title>
	<detailed_description>Patients metabolic syndrome ( MetSyn ) increase risk cardiovascular mortality morbidity . This increase cardiovascular risk attribute metabolic dysregulations like impaired glucose tolerance diabetes mellitus dyslipidemia , abdominal obesity arterial hypertension , promote oxidative stress inflammation together cause atherogenic environment . MetSyn well establish cardiovascular risk factor prevalence incidence MetSyn western world constantly rise 19.8 percent prevalence Germany 4 . Aldosterone predominantly synthesize adrenal gland . In addition , local aldosterone synthesis find heart vasculature aldosterone synthesis adipocytes discuss . Aldosterone exert effect via mineralocorticoid receptor ( MR ) . Besides well describe MR distal tubule kidney MR also detect organ vasculature paracrine mode action discuss . Recently describe , MR activate independent aldosterone hypertensive obese rat 1 . Aldosterone promote end organ damage mainly find cardiovascular system kidney . Inflammation activation different factor promotes fibroblast growth matrix production result myocardial fibrosis , vascular remodelling renal fibrosis . Aldosterone appear involved step process synthesis reactive oxygen specie , induction inflammation growth factor like TGF-Beta connective tissue growth factor . Taken together aldosterone - MetSyn- independent cardiovascular risk factor 5 . MetSyn aldosterone cardiovascular risk factor crucial importance note connection MetSyn aldosterone . In clinical study clearly demonstrate Renin Aldosterone patient MetSyn elevate 6 . Similar result obtain animal study obesity induce arterial hypertension increase renin aldosterone level 7-9 . In cross sectional study 397 participant impact aldosterone onset arterial hypertension MetSyn analyse . In study blood pressure associate aldosterone level aldosterone correlate waist circumference , insulin , HOMA index unfavourable lipid profile 10 . Other cross sectional study show direct correlation aldosterone level impair glucose metabolism patient without MetSyn 10 ; 11 . Taken together , aldosterone influence essential parameter MetSyn . Coincidentally parameter MetSyn stimulus increase aldosterone synthesis , i.e . visceral adipocytes 12 . In large scale clinical trial - RALES , EPHESUS , 4E 2 ; 3 ; 13 - inhibition MR proven beneficial patient congestive heart failure post myocardial infarction result confirm diabetic patient , know increase cardiovascular risk . In addition , diabetic patient significant less hypoglycaemic episode , indicate association MR inhibition glucose metabolism . Despite promising data MR inhibition cardiovascular mortality morbidity limit data impact MR inhibition metabolic , endocrine , inflammatory parameter patient MetSyn , yet suffer cardiovascular event . 1 . Nagase M , Fujita T. Mineralocorticoid receptor activation obesity hypertension . Hypertens Res 2009 ; 2 . Pitt B , Reichek N , Willenbrock R et al . Effects eplerenone , enalapril , eplerenone/enalapril patient essential hypertension leave ventricular hypertrophy : 4E-left ventricular hypertrophy study . Circulation 2003 ; 108 : 1831-1838 3 . Pitt B , Williams G , Remme W et al . The EPHESUS trial : eplerenone patient heart failure due systolic dysfunction complicate acute myocardial infarction . Eplerenone Post-AMI Heart Failure Efficacy Survival Study . Cardiovasc Drugs Ther 2001 ; 15 : 79-87 4 . Moebus S , Hanisch J , Bramlage P et al . Regional Differences Prevalence Metabolic Syndrome Primary Care Practices Germany . Deutsches Ärzteblatt 12 , 208-212 . 21-3-2008 . 5 . Milliez P , Girerd X , Plouin PF , Blacher J , Safar ME , Mourad JJ . Evidence increase rate cardiovascular event patient primary aldosteronism . J Am Coll Cardiol 2005 ; 45 : 1243-1248 6 . Egan BM , Papademetriou V , Wofford M et al . Metabolic syndrome insulin resistance TROPHY sub-study : contrasting view patient high-normal blood pressure . Am J Hypertens 2005 ; 18 : 3-12 7 . Carroll JF , King JW , Cohen JS . Hydralazine antihypertensive therapy obesity-related hypertension . Int J Obes Relat Metab Disord 2004 ; 28 : 384-390 8 . Carroll JF , Dwyer TM , Grady AW et al . Hypertension , cardiac hypertrophy , neurohumoral activity new animal model obesity . Am J Physiol 1996 ; 271 : H373-H378 9. de Paula RB , da Silva AA , Hall JE . Aldosterone antagonism attenuate obesity-induced hypertension glomerular hyperfiltration . Hypertension 2004 ; 43 : 41-47 10 . Kidambi S , Kotchen JM , Grim CE et al . Association adrenal steroid hypertension metabolic syndrome black . Hypertension 2007 ; 49 : 704-711 11 . Goodfriend TL , Egan B , Stepniakowski K , Ball DL . Relationships among plasma aldosterone , high-density lipoprotein cholesterol , insulin human . Hypertension 1995 ; 25 : 30-36 12 . Ehrhart-Bornstein M , Arakelyan K , Krug AW , Scherbaum WA , Bornstein SR . Fat cell may obesity-hypertension link : human adipogenic factor stimulate aldosterone secretion adrenocortical cell . Endocr Res 2004 ; 30 : 865-870 13 . Pitt D. ACE inhibitor co-therapy patient heart failure : rationale Randomized Aldactone Evaluation Study ( RALES ) . Eur Heart J 1995 ; 16 Suppl N : 107-110 14 . Grundy SM , Cleeman JI , Merz CN et al . Implications recent clinical trial National Cholesterol Education Program Adult Treatment Panel III Guidelines . J Am Coll Cardiol 2004 ; 44 : 720-732 15 . Raff U , Schmidt BMW , Schwab J , Achenbach S , Bär I , Schmieder RE . High incidence aldosterone breakthrough therapy resistant hypertension . Journal Hypertension Suppl . 2009 . 16 . Schmidt BMW , Raff U , Schwab J , Bär I , Schmieder RE . Eplerenone low dose induces regression leave ventricular hyprtrophy resistant hypertension . JASN Suppl . 2008 . 17 . Schmidt BM , Sammer U , Fleischmann I , Schlaich M , Delles C , Schmieder RE . Rapid nongenomic effect aldosterone renal vasculature human . Hypertension 2006 ; 47 : 650-655</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Male patient age &gt; 18 year mild uncomplicated primary arterial hypertension mean sit SBP ≥ 130 mmHg DBP ≥ 85 mmHg treat hypertension least 2 follow trait metabolic syndrome ( ATP III criterion ) : abdominal obesity ( abdominal girth ≥ 102 cm male ) , triglyceride level ≥ 150 mg/dL treatment elevate triglyzerides , HDL &lt; 40 mg/dL treatment low HDL fasting blood glucose ≥ 100 mg/dL ≤ 126 mg/dl . Written inform consent Agreement attend study visit plan protocol Patients without antihypertensive therapy mean blood pressure &gt; 160/100 mmHg Patients secondary hypertension Patients one antihypertensive agent maximally dose two ( less ) agent half ( less ) maximum approve dose Patients diabetes mellitus type 1 type 2 Smokers exsmokers &lt; 1 year Female patient ( prevent effect change endothelial function attributable menstrual cycle ) Patients sick sinus syndrome Patients high degree sinoatrial atrioventricular block ( IIIII ) Patients bradycardia ( &lt; 50 beats/min ) Patients malignant arrhythmias Patients know cardiovascular , disease Patients know cerebrovacular disease Patients peripheral occlusive artery disease Patients history epilepsy Patients severe hepatic disease ( serum GOT , GPT , gammaGT , AP , bilirubin &gt; 300 uppper normal range ) Patients renal disease define eGFR &lt; 60 ml/min/1,73m2 Patients history malignant disease within last 2 year Patients history depression Patients drug alcohol abuse Use investigational drug within 28 day study entry Known allergy know intolerance study drug Likelihood require treatment study period drug permit clinical study protocol , especially likelihood need additional antihypertensive medication Serious disorder may limit ability evaluate efficacy safety test drug ( ) , include cerebrovascular , cardiovascular , renal , respiratory , hepatic , gastrointestinal , endocrine metabolic , haematological oncological , neurological psychiatric disease Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol Mental condition render subject unable understand nature , scope possible consequence study Subject unlikely comply protocol , e.g . uncooperative attitude , inability return followup visit unlikelihood complete study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>